Two Cases of Thyrotoxicosis and Euglycemic Diabetic Ketoacidosis Under Sodium-glucose Transport Protein 2 Inhibitor Treatment.

Autor:	Hitsuwari T; Endocrinology and Diabetes Center, Yokohama Rosai Hospital, Japan., Tsurutani Y; Endocrinology and Diabetes Center, Yokohama Rosai Hospital, Japan., Yamane T; Endocrinology and Diabetes Center, Yokohama Rosai Hospital, Japan., Sunouchi T; Endocrinology and Diabetes Center, Yokohama Rosai Hospital, Japan., Horikoshi H; Endocrinology and Diabetes Center, Yokohama Rosai Hospital, Japan., Hirose R; Endocrinology and Diabetes Center, Yokohama Rosai Hospital, Japan., Hoshino Y; Endocrinology and Diabetes Center, Yokohama Rosai Hospital, Japan., Watanabe S; Endocrinology and Diabetes Center, Yokohama Rosai Hospital, Japan., Katsuragawa S; Endocrinology and Diabetes Center, Yokohama Rosai Hospital, Japan., Saitou J; Endocrinology and Diabetes Center, Yokohama Rosai Hospital, Japan.
Jazyk:	angličtina
Zdroj:	Internal medicine (Tokyo, Japan) [Intern Med] 2022 Oct 15; Vol. 61 (20), pp. 3069-3075. Date of Electronic Publication: 2022 Apr 02.
DOI:	10.2169/internalmedicine.8830-21
Abstrakt:	Thyrotoxicosis and sodium-glucose transport protein 2 inhibitors (SGLT2is) are associated with the induction of euglycemic diabetic ketoacidosis (euDKA). We herein report two cases of euDKA in patients with diabetes mellitus wherein both thyrotoxicosis and SGLT2i treatment were the underlying causes. One patient developed thyrotoxicosis during the course of type 2 diabetes mellitus, whereas the other patient was suspected of developing slowly progressive insulin-dependent diabetes mellitus during the course of Graves' disease. Although such cases are rare, there is some concern that similar cases may occur because of the increased frequency of SGLT2i use in recent years.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu